Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.

Key facts

Study ID

NCT07158411

Run by

Deciphera Pharmaceuticals, LLC

People needed

22

Starts

2025-11-20

Expected to finish

2026-01-30

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) from 18 to 32 kilogram per square meter (kg/m\^2).
• Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
• Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.

You may not qualify if…

• History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems and/or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease in the opinion of the Investigator.
• Unwilling or unable to comply with the requirements of the protocol.
• Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.

Where it is running

• Dr. Vince Clinical Research — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.